Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The company said this is the first new drug to treat the rare autoimmune disease in a decade. ChemoCentryx’s stock slipped 68.3% this year, while the broader S&P 500 SPX, +0.83% is up 16.1%.
View Article Origin Here
